Abstract:Atherosclerosis (AS) leads to atherosclerotic cardiovascular disease (ASCVD), the predominant cause of death worldwide. As traditional lipid-lowering therapies have encountered a bottleneck in dealing with diverse types of atherosclerotic plaques and ASCVD, alternative therapies that can target other mechanisms are urgently needed. Recent studies have revealed that AS is rooted in disrupted immune responses, such as chronic local inflammation and autoimmune responses, and immunotherapies have emerged as a nascent avenue to control plaque development owing to their satisfactory effects and high cost efficiency. The atherosclerotic immune microenvironment (AIME) is the microenvironment in which diverse immune responses occur dynamically. AIME is characterized by persistent inflammatory responses, shifted immunometabolism, and the formation of adventitial neuroimmune cardiovascular interfaces, all of which are regarded as prospective targets for AS immunotherapy. Recently, the advent of nanotechnology has advanced AS immunotherapy targeting the AIME. Manifold nanoplatforms have greatly enriched AS therapeutics owing to their multimodal imaging and multichannel intervention capabilities. Here, we offer an overview of AIME and discuss how nanomedicines can assist in AS diagnosis and intervention. We introduce nanoplatforms integrated with imaging techniques, such as magnetic resonance imaging, photoacoustic imaging, fluorescence imaging, positron emission tomography, and ultrasound imaging, which can target AIME to realize plaque diagnosis. Moreover, we elaborated on nanomaterials that regulate innate immune responses, adaptive immune responses, and aberrant immunometabolism to achieve AIME modulation. Furthermore, we highlight the possible future directions of AS therapeutics, with a focus on AIME-targeted nanomedicines.

Advances in nano-delivery systems based on diagnosis and theranostics strategy for atherosclerosis

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

Aiming at Early-Stage Vulnerable Plaques: A Nanoplatform with Dual-Mode Imaging and Lipid-Inflammation Integrated Regulation for Atherosclerotic Theranostics

Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy

Advances in stimulus-responsive nanomedicine for treatment and diagnosis of atherosclerosis

Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis

Advances of nanomedicine in treatment of atherosclerosis and thrombosis

Nanocarrier Based Targeting of Vascular Cell Adhesion Molecule-1 for Diagnosis and Treatment of Atherosclerosis: Current Status and Future Perspectives

Biomimetic nanomedicines for precise atherosclerosis theranostics

Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis

Recent Advances in Targeted Stimuli-Responsive Nano-Based Drug Delivery Systems Combating Atherosclerosis

Nanomedicine for Diagnosis and Treatment of Atherosclerosis

Recent progress in biomimetic nanomedicines based on versatile targeting strategy for atherosclerosis therapy

Design and Fabrication of Environmentally Responsive Nanoparticles for the Diagnosis and Treatment of Atherosclerosis

Biomimetic nanoparticles targeting atherosclerosis for diagnosis and therapy

Shedding New Light on Atherosclerosis Therapeutics: Nanomedicines Targeting Atherosclerotic Immune Microenvironment

Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

Engineering Nanoplatforms for Theranostics of Atherosclerotic Plaques

Advances of nanoparticle-mediated diagnostic and theranostic strategies for atherosclerosis

Biomimetic Nanoparticles for the Diagnosis and Therapy of Atherosclerosis